Filgrastim induces lymphocytosis, including all T cell subsets, and increased ex vivo interleukin (IL)-2 release as well as lymphocyte proliferation. Since Filgrastim is increasingly used in patients with human immunodeficiency virus (HIV) infection, the effect of Filgrastim on ex vivo cytokine production was determined. Whole blood from 8 healthy volunteers, 5 high-risk volunteers, and 31 HIV-infected outpatients was assayed for cytokine production in response to endotoxin (LPS) or staphylococcal enterotoxin B (SEB) in the presence or absence of 100 ng/mL Filgrastim. LPSinducible blood cytokine release of HIV-infected patients was not different from that of normal or high-risk volunteers. The suppressive effect of Filgrastim on LPS-inducible blood tumor necrosis factor-a and interferon-g formation in normal volunteers was not found in HIV-infected patients. Patients with advanced HIV infection showed reduced IL-2 and IL-4 release in the presence of SEB. In the presence of Filgrastim, IL-2 production was partially restored.
Filgrastim (granulocyte colony-stimulating factor, r-metHuG-HIV-infected patients are known to develop major defects of the immune signaling system [20] , in particular of the cytokine-CSF) is a hematopoietic growth factor primarily of neutrophilic granulocytes. It is used clinically to treat neutropenia due to mediator system. Some proinflammatory cytokines, such as tumor necrosis factor (TNF)-a and interferon (IFN)-g, are myelosuppressive chemo-or radiation therapy, severe chronic neutropenia, human immunodeficiency virus (HIV) infection, and found to be increased [5, 21 -23] and have been implicated in the promotion of viral replication [24] . More recently, lymphoother diseases [1] . HIV-infected patients may develop neutropenia because of the myelosuppressive effects of HIV or because kines, such as interleukin (IL)-2, have been thought to play an important role in the progression of HIV infection to AIDS. of some of the drugs used to treat these patients [2] . Both HIVinfected patients and HIV-infected leukocytes have shown a re-IL-2 formation by CD4 T cells appears to be mandatory in maintaining CD8 T cell control of viral replication [25] . A duced ability to produce G-CSF [3] [4] [5] . Neutropenia appears to be a risk factor and contributes to the increased incidence of switch from Th1-type lymphokines (primarily IL-2) to Th2-type lymphokines (IL-4, IL-10) was suggested to represent the infections in neutropenic HIV-infected patients [6] [7] [8] , and Filgrastim treatment has been shown to reverse neutropenia in HIVchange from asymptomatic HIV infection to AIDS [26] . Studies have shown that G-CSF has a widespread effect as infected patients and to decrease infection [9] [10] [11] [12] [13] [14] . A number of functional defects of neutrophils have been reported for HIVan immunomodulator controlling the functions and activity of mature neutrophilic granulocytes [27, 28] and has profound infected patients [15] [16] [17] teers treated with Filgrastim, the ex vivo cytokine release patFilgrastim has a beneficial effect on survival of patients with tern in stimulated whole blood was switched toward an antiin-AIDS, which does not appear to be entirely due to prevention flammatory pattern. In another volunteer trial, we have studied of infections [9, 19] .
the effect of Filgrastim treatment on lymphocyte functions (unpublished data). We found an increase not only in lymphocyte counts but also, in particular, in all T cell populations starting after 5 days of daily Filgrastim injection, with a relative maxi- (300 g, 5 min). Cell-free supernatants were collected, and aliquots and patients with HIV infection were stratified according to disease were frozen for cytokine measurements by EIA. Commercial EIAs severity, as indicated by CD4 cell count: ú500/mL (n Å 8), 200-were used throughout to determine cytokine levels: IL-2, TNF-a, 500/mL (n Å 9), 100-200/mL (n Å 6), and õ100/mL (n Å 8). All and IL-10 EIA kits from R&D Systems (Minneapolis), and ILsubjects with a current infection or history of Mycobacterium 4 (high sensitivity) and IFN-g kits from Biosource International avium infection, or who were receiving Filgrastim, steroid, or non-(Camarillo, CA). steroidal antiinflammatory drug therapy, were excluded. Patients Statistical considerations. Data are given as mean { SE. Sigwith HIV were allowed to continue standard care for their infecnificances between different blood donor groups were calculated tion.
by two-tailed Tukey-Kramer test for multiple comparisons. SigniThe high-risk control group consisted of patients who had risk ficances of the effects of Filgrastim versus vehicle control were factors for HIV infection but were seronegative for anti-HIV anticalculated by paired two-tailed Wilcoxon test (options of the InStat bodies by EIA. These subjects were enrolled at the time of posttest 2 program; GraphPad, San Diego). counseling. We have found that this group shows evidence of immune activation, even in the absence of any symptoms or signs of any active infection or other inflammatory process. (mean 27% reduction). However, in blood from HIV-infected patients, Filgrastim did not affect in vitro TNF release. LPSinducible IL-10 release was not changed in any blood donor group in the presence of Filgrastim during the incubation. IFNg release in response to LPS was suppressed in the presence of Filgrastim in normal volunteer blood (mean 43% reduction; P Å .008), but no significant effect was seen in blood from high-risk volunteers or HIV-infected patients ( figure 1C ).
Results

Study design and laboratory measurements.
Blood lymphokine response to SEB. The restricted sensitivity of available EIAs does not allow determination of IL-2 serum levels as a measure of endogenous production of this prime T lymphocyte growth factor. We therefore used a whole blood assay to determine lymphokine release capacity. We used the superantigen SEB to induce significant amounts of the lymphokines IL-2 and IL-4 after 48 h of incubation. Assayed amounts of IL-4 increased by extending the incubation time to 72 h. IL-2 release by whole blood is prone to considerable interindividual variances. However, these variances appear to reflect individual characteristics, since these differences remained unchanged in a study group of 20 healthy volunteers followed for several months (data not shown). Even among healthy blood donors, some failed to produce any significant amount of IL-2. In our study population, 3 of 7 normal volunteers and 3 of 5 high-risk volunteers failed to release significant amounts of IL-2 after 48 h of incubation in the presence of SEB. In HIVinfected patient blood, the number of nonproducers tended to increase with the stage of disease: 2 of 8 blood donors with CD4 cell counts ú500, 5 of 9 with counts between 200 and 500, 3 of 6 with counts between 100 and 200, and all 8 with õ100 CD4 cells/mL failed to produce significant amounts of IL-2 in response to SEB. In the presence of Filgrastim, however, 3 subjects with counts of 200 -500, who did not respond to SEB alone, released significant amounts of IL-2.
The SEB-stimulated blood samples from HIV-infected patients who had CD4 cell counts õ500/mL produced significantly less IL-2 than did samples from healthy volunteers or HIV-infected patients with CD4 cell counts ú500/mL from the ible cytokine release in blood from HIV-infected patients. Blood from same study population (table 2) (P Å .02). This impaired IL-HIV-negative controls, HIV-negative subjects at risk for HIV infec-2 production was partially restored in vitro by Filgrastim. Sigtion, and HIV-positive subjects with various CD4 cell counts/mL was nificantly higher levels of IL-2 were detected when whole blood incubated in presence of 10 mg/mL LPS for 24 h. In parallel incubaof HIV-infected patients with CD4 cell counts õ500/mL was tion, 100 ng/mL Filgrastim was added. Cytokines were determined in cell-free supernatants by EIA. Data are mean { SE. A, tumor incubated with SEB in the presence of Filgrastim (100 ng/mL), necrosis factor (TNF); B, interleukin (IL)-10; C, interferon (IFN)-g. compared with IL-2 levels seen in blood incubated without the addition of Filgrastim (P Å .037) (figure 2). Filgrastim did not affect SEB-stimulated IL-2 production in blood from healthy or high-risk volunteers or HIV-infected patients with CD4 cell decreasing CD4 cell count, had no effect on LPS-inducible cytokine release. counts ú500/mL (table 2) . Significant amounts of IL-2 were produced by blood samples Filgrastim is known to suppress whole blood TNF formation in vitro. This effect is even more pronounced ex vivo [29] .
from patients with CD4 cell counts õ100/mL only after 72 h of incubation ( figure 3A) . Even in patients with advanced HIV When 100 ng/mL Filgrastim was added to LPS-stimulated blood, TNF formation in blood from healthy volunteers tended infection, as evidenced by low CD4 cell counts, a trend toward increased IL-2 production in the presence of Filgrastim was to be lower in the presence of Filgrastim (P Å .08) for normal control (mean 29% reduction) and high-risk control volunteers observed (P Å .078).
/ 9d50$$se04 07-28-98 06:16:32 jinfa UC: J Infect proinflammatory to antiinflammatory cytokines [29] . Recently, a study in which volunteers were challenged with LPS 24 h after rHuG-CSF injection proved that this is also true in vivo SEB-inducible IL-4 was determined as an indicator of Th2 [30] . HIV-infected patients are known to express increased lymphokines. In normal volunteers, 9 { 2 pg of IL-4/mL of amounts of proinflammatory cytokines, such as TNF-a [31] blood was released after 48 h in response to SEB. IL-4 amounts and IFN-g [31, 32] . These proinflammatory mediators have further increased to 41 { 18 pg/mL of blood when the incubabeen shown to represent endogenous stimuli promoting HIV tion time was extended to 72 h (figure 3B). IL-4 response of replication [33 -35] . Thus, Filgrastim treatment could also reblood from HIV-infected patients tended to decrease in parallel duce the formation of proinflammatory factors in HIV-infected with the decrease in CD4 cell counts. Blood from HIV-infected patients. However, we found that the suppression of TNF-a patients with õ100 CD4 cells/mL released only 1.4 { 0.8 and IFN-g formation did not occur in HIV-infected patients' and 2.1 { 1.0 pg/mL of blood at 48 and 72 h of incubation, blood. However, it has to be noted that in our previous healthy respectively (figure 3B). Addition of Filgrastim in vitro did not volunteer studies [29] , TNF-a and IFN-g suppression by Filsignificantly alter SEB-inducible IL-4 release; that is, all 22 grastim was much more pronounced when treating donors com-HIV-infected patients released 14 { 5 pg of IL-4/mL of blood pared with mere addition of Filgrastim to blood in vitro. A on SEB stimulation, while 16 { 7 pg of IL-4/mL of blood was study of Filgrastim treatment of HIV-infected patients is curfound on SEB stimulation in the presence of Filgrastim. Thus, rently being undertaken to determine these antiinflammatory increased formation of the Th1 lymphokine IL-2 in the presence of Filgrastim is not accompanied by a concomitant decrease in release of the Th2 lymphokine IL-4.
Discussion
Patients at advanced stages of HIV infection showed reduced lymphokine (IL-2 and IL-4) release in response to SEB. Monokine (TNF-a, IL-10) and IFN-g release in response to LPS was not changed. In the presence of Filgrastim, a reduction in LPS-inducible TNF-a and IFN-g release capacity was noted in healthy volunteers but was not found in blood from HIVinfected patients. In contrast, Filgrastim increased SEB-inducible IL-2 formation in HIV-infected patient blood, while it had no effect in blood from healthy volunteers or HIV-infected / 9d50$$se04 07-28-98 06:16:32 jinfa UC: J Infect administration and lymphocytosis [36] . The increase in lymphocyte and CD4 cell counts is therefore of potential therapeutic benefit in the treatment of HIV disease. The mechanism by which Filgrastim improves IL-2 formation in HIV-infected patient blood remains obscure. Since this effect was not observed when Filgrastim was added to blood of healthy donors, a specific responsiveness of HIV-infected patient leukocytes must be assumed. Lymphocytes, at least from normal donors, in contrast to neutrophils and monocytes, do not bind G-CSF. Thus, an indirect effect by factors of either G-CSF -responsive leukocyte is most likely. However, monokine release was not significantly different in the presence of Filgrastim. The fact that Filgrastim restored IL-2 release to control donor levels argues in favor of G-CSF counteracting a suppressor present in HIV-infected patient blood. Future mechanistic studies will address the IL-2 release in response to immunostimuli other than SEB, IL-2 mRNA expression, and the effect of Filgrastim on isolated leukocyte populations.
Reduced IL-2 formation in HIV-infected patients is well known [23, 31, 37] and appears to be the cause of decreased lymphocyte proliferation and generation of cytotoxic T lymphocytes [38] . Whether this phenomenon, however, represents a crucial step in the pathogenesis of HIV disease is currently under discussion [39] . High levels of IL-2 formation were correlated with long-term nonprogression in HIV infection [40] , and lymphocyte responsiveness is an independent predictor for survival in patients with HIV and AIDS [41, 42] . The fact that have decreased CD4 cell counts, and treatment designed to increase IL-2 formation and CD4 cell counts may be particularly relevant to this patient population. Attenuated production of IL-2 in advanced HIV infection appears to play a major role effects. However, in line with the lack of activity of Filgrastim in vitro on TNF-a and IFN-g release by HIV-infected patient in this loss of T helper cells. One part of this study, therefore, examined the effect of Filgrastim in vitro on IL-2 production blood, no clinical effect of Filgrastim treatment on virus load (the parameter most closely reflecting viral replication) has yet in blood from patients with HIV infection. IL-2 is a lymphokine, the major growth factor for lymphocytes. In addition been reported.
In a parallel volunteer study, we determined the effects of to the proliferation of CD4 and CD8 lymphocytes, IL-2 also enhances cytolytic activity of suppressor cells, enhances NK Filgrastim treatment of volunteers on ex vivo lymphocyte counts and functions (unpublished data). In normal healthy cell activity, and increases IFN-g production. IL-2 infusions and subcutaneous injections cause a marked increase in the volunteers, Filgrastim also increased the total number of circulating lymphocytes. The Filgrastim-induced lymphocytosis was absolute CD4 lymphocyte count in patients with HIV infection. There is also potential benefit of increased numbers and cytodose-dependent and reached a transient maximum after Ç8 days of daily administration. Part of the total increase in lymlytic activity of CD8 lymphocytes, as these are the major effector cells in the host response against HIV infection. phocytes was due to an increase in the number of T helper (CD4) cells. In addition, Filgrastim treatment of volunteers An impairment in IL-2 production in patients with CD4 cell counts õ500/mL was reversed in the presence of Filgrastim induced an increase in production of IL-2 by stimulated peripheral blood mononuclear cells as well as a simultaneous augmenwhich is not associated with the flu-like symptoms observed with subcutaneous injections of IL-2. Endogenous IL-2 formatation of lymphocyte proliferation 24 h after the first Filgrastim injection. Increased endogenous production of this lymphokine tion is believed to play a key role in the pathogenesis of HIV infection. The CD8 cells maintained by CD4 cell -derived could explain the observed increase in lymphocyte counts, particularly as the timing of the IL-2 and lymphocyte increases IL-2 are known to suppress, in turn, HIV replication in CD4 cells [25, 43] . In line with these observations, recent studies corresponds with the known delay between exogenous IL-2
